A Phase 3 interventional study of Islatravir and Placebo to FTC/TDF in HIV-I, Human Immunodeficiency Virus Type 1 and Prophylaxis, sponsored by Merck Sharp & Dohme LLC. Terminated at 24 sites in 3 countries. Open to female participants aged 16 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection. The study will compare oral ISL taken once a month with standard-of-care medication for prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per day. The primary hypothesis is that oral ISL is more effective than FTC/TDF at reducing the incidence rate per year of confirmed HIV-1 infections.
Based on laboratory findings of decreased lymphocyte and CD4+ T-cell counts across the islatravir program, dosing of blinded study intervention was halted on 13-Dec-2021 and screening and randomization of new participants was ended. Blinded assessments conducted prior to this date are designated as Study Part 1. During Study Part 2, participants from Part 1 have the option to receive daily open-label FTC/TDF while continuing in the study for safety monitoring. Study Part 3 was added to unblind each participant's Part 1 study intervention assignment, continue participants on FTC/TDF, and monitor safety.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 730 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ISL (islatravir) once monthly AND placebo to FTC/TDF (emtricitabine/tenofovir disoproxil) once daily. Following study-wide cessation of ISL administration, participants had the option to receive open-label FTC/TDF administered once daily.
Drug: Islatravir · Drug: Placebo to FTC/TDF
FTC/TDF (TRUVADA™ or generic product emtricitabine/tenofovir disoproxil) administered once daily. Placebo to ISL (islatravir) administered once monthly. Following study-wide cessation of ISL administration, participants had the option to continue on open-label FTC/TDF. Placebo was no longer administered once open label treatment began.
Drug: FTC/TDF · Drug: Placebo to ISL
Oral 60 mg tablet administered once monthly during Part 1.
Also known as: MK-8591
0 mg tablet administered once daily during Part 1.
Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
Also known as: TRUVADA™, Emtricitabine/Tenofovir disoproxil, Emtricitabine/Tenofovir disoproxil fumarate
0 mg tablet administered orally once monthly in Part 1.
Incidence Rate Per Year of Confirmed HIV-1 Infection Among Participants During Blinded Treatment +42 Days Post-Blind
Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections during the assessment period divided by the number of person-years in the arm. Data are based on participants with confirmed HIV-1 infection. The originally planned primary statistical analysis was removed via amendment when open-label treatment was initiated.
Time frame: Up to approximately 325 days
Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment + 42 Days Post-Blind
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.
Time frame: Up to approximately 325 days
Number of Participants Who Discontinued Blinded Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued blinded study treatment due to an AE will be reported for each treatment arm.
Time frame: Up to 283 days
Incidence Rate Per Year During Blinded Treatment of Confirmed HIV-1 Infection Among ISL-Treated Participants
Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections during the assessment period divided by the number of person-years in the arm. Data are based on participants with confirmed HIV-1 infection. The originally planned secondary statistical analysis was removed via amendment when open-label treatment was initiated.
Time frame: Up to approximately 237 days
| Milestone | ISL QM | FTC/TDF QD |
|---|---|---|
| Started | 364 | 366 |
| Treated per protocol arm design | 362 | 365 |
| Received open-label ftc/tdf | 343 | 345 |
| Completed | 0 | 0 |
| Not completed | 364 | 366 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Withdrawal by subject | 21 | 19 |
| Withdrew: Lost to follow-up | 31 | 34 |
| Withdrew: Study terminated by sponsor | 308 | 309 |
| Withdrew: Randomized in error | 2 | 1 |
| Withdrew: Other | 0 | 1 |
Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections during the assessment period divided by the number of person-years in the arm. Data are based on participants with confirmed HIV-1 infection. The originally planned primary statistical analysis was removed via amendment when open-label treatment was initiated.
| Percentage of Participants/Person-Year | ISL QM | FTC/TDF QD |
|---|---|---|
| Incidence Rate Per Year of Confirmed HIV-1 Infection Among Participants During Blinded Treatment +42 Days Post-Blind | 0.000 | 0.000 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.
| Participants | ISL QM | FTC/TDF QD |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment + 42 Days Post-Blind | 198 | 255 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued blinded study treatment due to an AE will be reported for each treatment arm.
| Participants | ISL QM | FTC/TDF QD |
|---|---|---|
| Number of Participants Who Discontinued Blinded Study Treatment Due to an AE | 2 | 4 |
Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections during the assessment period divided by the number of person-years in the arm. Data are based on participants with confirmed HIV-1 infection. The originally planned secondary statistical analysis was removed via amendment when open-label treatment was initiated.
| Percentage of Participants/Person-Year | ISL QM |
|---|---|
| Incidence Rate Per Year During Blinded Treatment of Confirmed HIV-1 Infection Among ISL-Treated Participants | 0.000 |
Collected over Blinded arms and mistaken treatment arm: Up to approximately 325 days Open-label arms: Up to approximately 639 days (starting 42 days after last blinded treatment; includes the time leading up to first open-label treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ISL QM | 1/364 (0.3%) | 4/362 (1.1%) | 145/362 (40.1%) |
| ISL QM > Open-Label FTC/TDF | 0/343 (0%) | 13/343 (3.8%) | 292/343 (85.1%) |
| FTC/TDF QD | 0/366 (0%) | 2/365 (0.5%) | 210/365 (57.5%) |
| FTC/TDF > Open-Label FTC/TDF Second Course | 0/345 (0%) | 23/345 (6.7%) | 284/345 (82.3%) |
| FTC/TDF-Treated Without Randomization | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Event | ISL QM | ISL QM > Open-Label FTC/TDF | FTC/TDF QD | FTC/TDF > Open-Label FTC/TDF Second Course | FTC/TDF-Treated Without Randomization |
|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/362 | 2/343 | 1/365 | 4/345 | 0/1 |
| Prolonged labourPregnancy, puerperium and perinatal conditions | 0/362 | 0/343 | 0/365 | 2/345 | 0/1 |
| GastritisGastrointestinal disorders | 0/362 | 1/343 | 0/365 | 0/345 | 0/1 |
| Aspartate aminotransferase increasedInvestigations | 0/362 | 1/343 | 0/365 | 0/345 | 0/1 |
| Gamma-glutamyltransferase increasedInvestigations | 0/362 | 1/343 | 0/365 | 0/345 | 0/1 |
| Abnormal loss of weightMetabolism and nutrition disorders | 0/362 | 1/343 | 0/365 | 0/345 | 0/1 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 0/362 | 1/343 | 0/365 | 0/345 | 0/1 |
| Loss of consciousnessNervous system disorders | 0/362 | 1/343 | 0/365 | 0/345 | 0/1 |
| SyncopeNervous system disorders | 0/362 | 1/343 | 0/365 | 0/345 | 0/1 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/362 | 1/343 | 0/365 | 0/345 | 0/1 |
| Event | ISL QM | ISL QM > Open-Label FTC/TDF | FTC/TDF QD | FTC/TDF > Open-Label FTC/TDF Second Course | FTC/TDF-Treated Without Randomization |
|---|---|---|---|---|---|
| Bacterial vaginosisInfections and infestations | 28/362 | 158/343 | 57/365 | 143/345 | 0/1 |
| Vulvovaginal candidiasisInfections and infestations | 13/362 | 114/343 | 29/365 | 109/345 | 0/1 |
| Upper respiratory tract infectionInfections and infestations | 21/362 | 70/343 | 12/365 | 55/345 | 0/1 |
| HeadacheNervous system disorders | 43/362 | 61/343 | 53/365 | 56/345 | 0/1 |
| Chlamydial infectionInfections and infestations | 4/362 | 58/343 | 17/365 | 55/345 | 0/1 |
| Influenza like illnessGeneral disorders | 4/362 | 45/343 | 3/365 | 41/345 | 0/1 |
| Heavy menstrual bleedingReproductive system and breast disorders | 13/362 | 33/343 | 11/365 | 39/345 | 0/1 |
| NauseaGastrointestinal disorders | 19/362 | 13/343 | 41/365 | 13/345 | 0/1 |
| Urinary tract infectionInfections and infestations | 0/362 | 31/343 | 5/365 | 34/345 | 0/1 |
| Vaginal dischargeReproductive system and breast disorders | 7/362 | 30/343 | 11/365 | 30/345 | 0/1 |
The baseline characteristics population includes all randomized participants who received study drug.
| Age, Continuous(Years) | ISL QM | FTC/TDF QD | Total |
|---|---|---|---|
| Mean | 26.0 ± 6.1 | 26.1 ± 6.3 | 26.1 ± 6.2 |
| Sex: Female, Male(Participants) | ISL QM | FTC/TDF QD | Total |
|---|---|---|---|
| Female | 362 | 365 | 727 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | ISL QM | FTC/TDF QD | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 13 | 24 |
| Not Hispanic or Latino | 329 | 330 | 659 |
| Unknown or Not Reported | 22 | 22 | 44 |
| Race (NIH/OMB)(Participants) | ISL QM | FTC/TDF QD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 5 | 6 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 334 | 338 | 672 |
| White | 19 | 15 | 34 |
| More than one race | 3 | 4 | 7 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Feb 2021 to primary completion in Jul 2023, 28 months.
Results were first posted in Aug 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Islatravir
Acquired Immunodeficiency Syndrome →